Using metabolomics to predict treatment response in rectal cancer
Metabolomic Profiles as Predictors of Treatment Response and Toxicities in Locally Advanced Rectal Cancer Undergoing Total Neoadjuvant Therapy
This study is testing whether certain substances in the body can help predict how well patients with advanced rectal cancer will respond to a specific treatment plan and if they might face any side effects.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 250 (estimated) |
| Ages | 20 Years and up |
| Sex | All |
| Sponsor | Chang Gung Memorial Hospital Academic / other |
| Drugs / interventions | radiation, chemotherapy |
| Locations | 1 site (Guishan, Taoyuan) |
| Trial ID | NCT06831669 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the metabolomic profiles of patients with locally advanced rectal cancer who are scheduled to receive total neoadjuvant therapy (TNT). By collecting blood, urine, tissue, and fecal samples at various stages of treatment, the study seeks to identify specific metabolites that can predict how well patients will respond to TNT and the likelihood of experiencing treatment-related toxicities, such as radiation proctitis. The goal is to enhance precision health by selecting patients who are most likely to benefit from TNT while minimizing complications.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals with histologically confirmed adenocarcinoma of the rectum who are scheduled to receive total neoadjuvant therapy.
Not a fit: Patients who have previously undergone pelvic radiation therapy or have inflammatory bowel disease may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to personalized treatment plans that improve outcomes and reduce side effects for rectal cancer patients.
How similar studies have performed: There is a growing body of evidence suggesting that metabolomics can effectively predict treatment response and toxicity in cancer patients, although most prior studies have focused on long-course chemoradiotherapy.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically confirmed adenocarcinoma of the rectum * Scheduled to receive total neoadjuvant therapy Exclusion Criteria: * Previous pelvic radiation therapy * Inflammatory bowel disease
Where this trial is running
Guishan, Taoyuan
- Linkou Chang Gung Memorial Hospital — Guishan, Taoyuan, Taiwan (Recruiting)
Study contacts
- Study coordinator: Eric Yi-Liang Shen, PhD
- Email: pts@cgmh.org.tw
- Phone: 0975366392
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.